Press releases

Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...

Confirms clinical value and cost-effectiveness of spinal cord stimulation

Leading carotid stent in Europe and other international markets now available in the United States

"For the second consecutive quarter, we maintained our strong U.S. DES market share leadership," said President and CEO Jim Tobin

Landmark trial provides new insight for physicians

Outcomes from the study of 22,000 patients with coronary artery disease continues to show impressive safety and efficacy data

New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients

Company moves up Q3 earnings release date

TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts

Joint efforts will focus on intravascular ultrasound (IVUS)

Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...

Two-year pooled ARRIVE data showed the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes

New coronary stent features thin struts designed for more uniform drug delivery

TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month

Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions

The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling

Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.

PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent

Judgment against Company entered in a patent case filed in 1997; Company to appeal

Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis

A live webcast and replay of the September 25 session will be available

Boston Scientific Corporation (NYSE: BSX) announced today a decision by the United States District Court in Delaware. The case involves a patent...

A live webcast and replay of the Tuesday, September 16 session will be available

Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)

Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)

Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award

Company to present data from landmark SYNTAX clinical trial

"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A live webcast and replay of the July 22 conference call will be available

Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain

Transactions further Company's plans to focus on core businesses and increase shareholder value

Fitch also reaffirmed the Company's long-term credit rating of BB+

A live webcast and replay of the June 11 session will be available

Company announces management changes and further organizational consolidation

Environmentally focused improvements are hallmark of renovations to Endosurgery headquarters

Transaction follows the definitive agreement announced on April 16

Boston Scientific defenses in patent infringement case to be heard by the U.S. District Court in Marshall, Texas on July 31.

Positive results presented at Digestive Disease Week 2008

New size allows for treatment of smaller-diameter diseased saphenous vein grafts

ACUITY® Spiral lead has smallest left ventricular lead tip profile in the industry

Results of international, multi-center registry to be presented at conference

ALTITUDE clinical science initiative will provide insights to ICD and CRT-D device therapy

COGNIS™ CRT-D and TELIGEN™ ICD represent entirely new platforms

Provides valuable insights for diabetic patients, who are often at higher risk for adverse events and repeat stenting procedures

Boston Scientific welcomed two-year results from the SPIRIT III clinical trial, presented at the 2008 EuroPCR Scientific Program in Barcelona.

Company supports efforts of International Diabetes Federation to promote worldwide diabetes care and prevention

"We are very pleased with the decision by the Canadian Federal Court dismissing this case," said Boston Scientific's Chief Operating Officer.

ALTRUA™ is Company's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity.

Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA™ family of pacemakers. ALTRUA is Boston...

Ruling from World Intellectual Property Organization (WIPO) arbitration panel finds no infringement

A live webcast and replay of the May 6 conference session will be available

A live webcast and replay of the April 30 session will be available.

MADIT-CRT trial designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors

Award recognizes Boston Scientific's successful use of electronic transactions to improve supply chain efficiency for customers and suppliers

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said CEO Jim Tobin.

Company plans to launch product immediately

Acquisition follows a 2007 development agreement to pursue therapeutic solutions for atrial fibrillation, or "Afib"

Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients

ACUITY® Steerable lead also receives reimbursement approval; Company plans to launch product immediately

A live webcast and replay of the April 22 conference call will be available.

Nationally known attorney specializing in medical device and pharmaceutical litigation; will serve on the Company's Executive Committee

Judgment entered in favor of Guidant and its former directors/officers

Data was presented at SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents

At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes

Sale is the latest example of Company's commitment to realigning its cost structure; overall goal is to strengthen Boston Scientific for the future

Two-year outcomes confirm the favorable results seen in previous clinical trials

One-year pooled ARRIVE data showed similarly low rates of stent-related cardiac death, myocardial infarction, stent thrombosis, and major cardiac events across the two patient subsets

Presentations to include clinical data for the TAXUS® paclitaxel-eluting coronary stent in a variety of high-risk patient populations

A live webcast and replay of the March 18 session will be available. Learn how to tune in

ACUITY® Spiral lead offers flexibility for placement in small, medium and large veins

Forty implants of COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD) performed in 14 hospitals in six countries

Jay J. Schnitzer, M.D., Ph.D. to join Company's Clinical Sciences organization effective March 24

Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System

Completes Company's previously announced plans to divest five non-strategic businesses

Company plans to seek to overturn patent infringement lawsuit verdict in post-trial motions

PROENCY will provide real-world clinical data on the PROMUS™ Stent

"The turn that began last quarter continued this quarter, with strong adjusted earnings and record sales," said Jim Tobin, President and Chief Executive Officer

'Close the Gap' brings together advocates from cardiologists to coaches

A live webcast and replay of the February 6 session will be available.

NEJM article is entitled "A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications"

A live webcast and replay of the February 5 conference call will be available

CE Mark approvals are for COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD)

Ruling finds the NIR® stent, formerly sold by Company, infringed one claim of a patent owned by Johnson & Johnson

Divestitures are part of ongoing efforts to simplify operating model and restore profitable growth

Company retains ownership of Pain Management business

A live webcast and replay of the January 9 session will be available

LIVIAN™ CRT-D is specifically designed to monitor heartbeats in heart failure patients and deliver small electrical impulses that may improve the heart's pumping ability

TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent

In addition to the two sales announced today, Boston Scientific has also recently announced agreements to sell its Cardiac Surgery, Vascular Surgery and Auditory businesses

The two stent systems are identical products; would be covered by the same FDA approval

A live webcast and replay of the December 5 session will be available

A live webcast and replay of the November 28 session will be available

Settles claims associated with product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant last year

Integration links LATITUDE® Patient Management system to GE's Electronic Medical Record (EMR) system

Getinge Group, a global provider of healthcare equipment and systems, to buy the two businesses for cash price of $750 million

Company believes the finding of patent infringement is in error and will request the judge to overturn it

Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company

Studies evaluated the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease